Home Blog Page 1243

Newmark Releases its 2026 Seoul Office Market Outlook, Highlighting Strengthening Fundamentals

By
Advertorial Desk
-

Seoul Office Market Enters Structural Reallocation Phase After Record KRW 22.9 Trillion Recovery

NEW YORK and SEOUL, Korea, Feb. 3, 2026 /PRNewswire/ — Newmark Group, Inc. (Nasdaq: NMRK) (“Newmark”), a leading commercial real estate advisor and service provider to global corporations, institutional investors, and owners and occupiers, today released its 2026 Seoul Office Market Outlook for Capital Markets and Leasing, highlighting a robust occupier market alongside a rapidly recovering capital markets environment.

Newmark Group, Inc.
Newmark Group, Inc.

Executive Commentary

“Seoul’s office market remains fundamentally resilient across both occupier and capital markets,” said John Pritchard, Managing Director and Country Head of Newmark Korea. “We are seeing a strategic reallocation of demand, as corporates and investors focus on higher-quality, more efficient assets. Tenant demand is increasingly concentrating in prime and newly developed offices, while aging stock faces growing competitive pressure.”

Judy Jang, Executive Director, Head of Research– Korea, added, “Following the record KRW 22.9 trillion transaction year in 2025, capital is returning to the market as confidence in pricing and income stability improves. Looking ahead, asset-level differentiation will be the defining factor for performance, with market polarization becoming a foundational feature of the Seoul office landscape.”

Occupier Market: Structural Reallocation, Not Demand Exit

Corporate relocations across Seoul in 2025 reflect a fundamental shift in workplace strategy rather than cost-driven exits. Major occupiers are consolidating, upgrading and repositioning their office footprints to support hybrid work, collaboration and talent attraction.

Tenant decision-making is increasingly driven by building quality, ESG performance, accessibility and workplace experience. As a result, demand continues to concentrate in prime and newly delivered offices, while aging and non-renovated stock faces growing competitive pressure. This mirrors trends observed across global gateway cities such as London, New York, Singapore and Tokyo.

Capital Markets: Recovery Turns Fundamental

Seoul’s office investment market staged a strong recovery in 2025, supported by stabilizing interest rates, improving financing conditions and the return of institutional capital. Core and prime assets in Central Business District (CBD), Gangnam Business District (GBD) and Yeouido Business District (YBD) demonstrated strong downside protection, supported by stable leasing fundamentals and long-term investor conviction.

Beyond the traditional core, investor interest is expanding into function-driven office clusters such as Seongsu–Seoul Forest, Magok, Pangyo–Bundang and Sangam DMC, reflecting a broader reallocation of office demand.

Supply & Development Cycle

Rising construction costs and permitting delays have pushed Seoul’s next major supply wave into 2028–2029, extending the current period of limited new completions.

Near-term deliveries in 2026, including G1 Seoul, Rene Square and Eul Tower, will test short-term absorption, but pre-leasing momentum suggests that demand for prime assets remains intact. The delayed development pipeline is expected to support rental stability in prime assets while creating a medium-term inflection point for the market cycle.

Submarket Outlook

  • CBD: Short-term vacancy volatility driven by large corporate relocations, with asset repositioning accelerating and the major supply cycle delayed to 2028–2029.
      
  • GBD: Low vacancy due to a limited development pipeline, supported by strong headquarters-driven leasing and owner-occupier demand.
      
  • YBD: Resilient financial sector demand, portfolio restructuring and redevelopment-driven tenant reshuffling, with future supply largely owner-occupied.

Why Seoul Matters to Global Capital

  • Asia’s fourth-largest economy
  • Global hub for technology, finance, content, biotech and advanced manufacturing
  • One of Asia’s most liquid office investment markets
  • Deep domestic institutional capital base
  • Growing cross-border investor participation

About Newmark
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate, seamlessly powering every phase of the property life cycle. Newmark’s comprehensive suite of services and products is uniquely tailored to each client, from owners to occupiers, investors to founders, and startups to blue-chip companies. Combining the platform’s global reach with market intelligence in both established and emerging property markets, Newmark provides superior service to clients across the industry spectrum. For the twelve months ended September 30, 2025, Newmark generated revenues of over $3.1 billion. As of September 30, 2025, Newmark and its business partners together operated from approximately 170 offices with over 8,500 professionals across four continents. To learn more, visit nmrk.com or follow @newmark.

Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the Company’s business, results, financial position, liquidity, and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.

Carbyne Fitness and IFPA Singapore Publish Study Revealing the Gender Gap Between Personal Training and Home Gyms

By
Advertorial Desk
-

SINGAPORE – Media OutReach Newswire – 3 February 2026 — A new joint study by Carbyne Fitness and IFPA Singapore has revealed a striking and persistent gender divide in Singapore’s fitness habits: while 80% of home gym users are male, over 60% of individuals actively seeking personal trainers are female.

The findings, based on Carbyne Fitness’ customer data and an online database of personal training enquiries compiled by IFPA Singapore’s personal trainers, point to two fundamentally different approaches to exercise motivation and engagement between men and women.

A Tale of Two Fitness Journeys
The data suggests that men overwhelmingly prefer self-directed fitness, buying equipment such as adjustable dumbbells, benches, and racks for home use. Women, on the other hand, are more inclined toward guided training experiences led by certified professionals.

According to Brian Chang, founder of Carbyne Fitness and IFPA Singapore, this split reveals not just gender preferences, but deeper social and psychological factors shaping how Singaporeans exercise.

“Men often see fitness as something they should be able to handle on their own, like asking for help somehow means they’re not strong enough,” said Chang. “That’s why many men would rather train themselves than work with a coach. Ladies, on the other hand, are usually more open to learning and getting guidance. They see working with a coach not as weakness, but as a smart way to improve safely and effectively.”

The Male Home Gym Boom
The pandemic sparked a surge in home gym investments, and Carbyne Fitness has been at the forefront of this trend. Its adjustable dumbbells and adjustable kettlebells have become popular among working professionals looking to save time and train efficiently at home.

Carbyne Fitness’ customer data revealed that four in five customers are male. “The home gym trend among men is here to stay,” Chang explained. “They appreciate the convenience, privacy, and long-term savings. For many, it’s not just fitness equipment, it’s a personal investment in staying strong and independent as they age.”

However, with about 58% of Carbyne Fitness customers living in HDB flats, 26% in condominiums, and 16% in landed properties, many still hold the misconception that home workouts, especially in smaller HDB or condo spaces, aren’t practical or effective. Landed property owners make up less than 5% of Singapore’s dwellings, yet account for 16% of Carbyne Fitness’ customers.

Dwelling Type National Share (SingStat) Carbyne Customer Share Index (Representation)
HDB (Public Housing) 72.0% 58.5% 0.81 (Under-indexed)
Condominiums 23.3% 25.6% 1.10 (Over-indexed)
Landed Properties 4.7% 15.9% 3.38 (Heavily Over-indexed)

“One of the most common reasons people give for not buying home gym equipment is that they ‘don’t have the space,'” said Chang. “But in reality, a proper home setup doesn’t need much room; a good pair of adjustable dumbbells and a bench can fit comfortably within just one square meter if you choose the right equipment.”

Why Women Seek Trainers
In contrast, IFPA Singapore’s training enquiries show that a majority of personal training clients are female. Of the 392 Singapore-based individuals who sought personal training, 63% were women, even though men still represent the majority of gym members nationwide.

Category Male % Female % Dominant Characteristic
Home Gym Buyers (Carbyne) 80% 20% High Autonomy
PT Seekers (IFPA) 37% 63% Guidance Seeking
Population (DOS 2025) 49.3% 50.7% Balanced

“This reflects a growing confidence among women to take charge of their fitness journey,” said Chang. “But it also shows that women tend to prioritize safety and proper form. They are more willing to invest in expert guidance rather than risk injury from unguided workouts.”

Many female clients, Chang adds, have goals that extend beyond appearance: postnatal recovery, strength for caregiving, or functional fitness for daily life.

“It’s not just about aesthetics anymore,” he said. “Women are recognizing that strength training builds long-term resilience, both physically and mentally.”

Implications for Singapore’s Fitness Industry
The gender divide uncovered by Carbyne Fitness and IFPA Singapore also points to structural gaps in how Singapore’s fitness ecosystem is organized, particularly the limited avenues for personal trainers to operate independently.

Most commercial gyms and public facilities, including ActiveSG gyms, do not permit outside personal trainers to conduct sessions within their premises. Trainers who are not employed directly by these gyms are often barred from coaching clients on-site, regardless of their certification or insurance coverage.

This restriction limits both consumer choice and career opportunities within the industry. For clients, especially women who prefer guided training but may not want to commit to an expensive gym membership, the policy creates a barrier to accessing affordable, flexible coaching. For freelance trainers, it restricts their ability to build a sustainable practice or serve niche communities such as seniors, postnatal women, or first-time exercisers.

“Many independent trainers tell us their biggest challenge isn’t finding clients; it’s finding space,” said Chang. “There’s a clear demand for affordable, accessible training environments, but the system hasn’t caught up yet.”

As a result, more trainers have turned to parks, void decks, or private studios, and a growing number of clients are exploring home-based personal training, sometimes with only a pair of resistance bands. This shift reflects broader lifestyle preferences: Singaporeans want convenience, privacy, and trust, not just a gym membership.

The study suggests that expanding access to personal training across shared and public fitness spaces could help Singapore move toward a more inclusive, community-driven fitness culture, one that empowers both male and female participants to train safely, confidently, and sustainably at every stage of life.

Volunteering for the Silver Generation
Both Carbyne Fitness and IFPA Singapore are working to build a more inclusive fitness culture through the Silver Strength volunteer program, which runs weekly strength sessions for seniors using resistance bands, adjustable dumbbells, and other small equipment at Active Ageing Centers across Singapore.

The initiative, funded by the National Youth Council, empowers older adults to stay strong, mobile, and independent, while giving volunteers the chance to make a direct impact in their communities.

“Silver Strength is more than fitness. It is about bridging intergenerational gaps and helping seniors live confidently and age with strength,” said Chang.

To sign up as a volunteer, visit getcertifiedpt.com/silver-strength.

About the Study
The gender distribution insights were derived from:

  • Carbyne Fitness customer data, representing over 1,000 unique customer interactions across Singapore between January 2024 and September 2025.
  • IFPA Singapore’s independent observation of 392 prospective client profiles compiled between October 2025 and December 2025.

While the sample sizes differ, both data sets converge on a clear narrative: Singapore’s home gym market is predominantly male, while personal training demand is female-driven.

The full research can be accessed on https://carbyne.sg/blogs/articles/revealing-the-gender-gap-between-personal-training-and-home-gyms.
Hashtag: #CarbyneFitness

The issuer is solely responsible for the content of this announcement.

About Carbyne Fitness

Carbyne Fitness is a Singapore-based fitness equipment company focused on delivering space-efficient, performance-driven home gym solutions for modern lifestyles. Best known for its space-saving gym equipment such as adjustable dumbbells and foldable treadmills, Carbyne helps professionals, families, and seniors train effectively at home without compromising on quality or safety.

Learn more at:

About IFPA Singapore

IFPA Singapore, operated by Get Certified PT, is the official Singapore operator of the International Fitness Professionals Association (IFPA), delivering internationally accredited personal training education and professional development. IFPA Singapore focuses on producing industry-ready practitioners through competency-based, real-world training.

Learn more at:

Asian Smart Medical Online Exhibition 2026: Connecting Smart Medical Suppliers with Global Buyers

By
Advertorial Desk
-

TAIPEI, TAIWAN – Media OutReach Newswire – 3 February 2026 – The Asian Smart Medical Online Exhibition 2026 (Medical Asia 2026) is a premier hybrid exhibition designed to seamlessly connect Asian medical suppliers, importers, and exporters with buyers from around the world. Taking place from February 3, 2026, to May 31, 2026, Medical Asia 2026, this four-month online exhibition provides exhibitors with an exceptional platform to showcase their brands, products, and innovations to a truly global audience.

Asian Smart Medical Online Exhibition 2026: Connecting Smart Medical Suppliers with Global Buyers

Organized by AsianNet and TradeAsia (www.e-tradeasia.com), Medical Asia has been successfully facilitating international medical trade since its launch in 2024 , earning a strong reputation for high-quality participation and tangible business outcomes. In 2026, Medical Asia extends its exhibition period to strategically align with major global healthcare and medical industry events, including Medical Design & Manufacturing West, Arab Health, HIMSS Global Health Conference & Exhibition, MEDICAL JAPAN [Osaka], and Hospitalar Sao Paulo. This extended timeline enables international buyers to engage with multiple key events simultaneously, creating a more efficient and streamlined sourcing experience.

By participating in Medical Asia 2026, exhibitors can expect enhanced global exposure, broader networking opportunities, and increased potential for sustainable business growth, all while reaching a larger and more diverse international buyer base through a flexible and cost-effective hybrid exhibition model.

Medical Asia 2026 features a robust lineup of respected Taiwanese manufacturers, including industry leaders such as Perfect Medical and many more. These companies will present thousands of the latest smart medical industry products and technologies, covering a wide array of sectors crucial to modern manufacturing and production.

The event will feature an extensive selection from top manufacturers, covering categories such as Medical Devices & Clinical Equipment, Medical Supplies & Nursing Consumables, Healthcare Facility Furniture & Logistics Equipment, Emergency & Clinical Patient Monitoring Equipment, Rehabilitation & Physiotherapy Equipment / Consumables, Pharmaceutical Manufacturing, Packaging & Inspection Machinery, Medical-grade Wearables & Remote Patient Monitoring (RPM) Devices, Clinical Laboratory & IVD Analyzers, Medical-grade Materials & Components (Plastics / Rubber / Silicone, etc.), and Home Health Care Products. With thousands of the latest products, accessories, and equipment on display, the exhibition promises to be both comprehensive and highly professional. Attendees will gain valuable insights into the latest innovations and developments across the smart medical industry.

Visit the Online Exhibition:
https://www.etradeasia.com/online-show/42/Asian-Smart-Medical-Online-Exhibition-2026.html

In today’s rapidly evolving global environment, online platforms play a crucial role in breaking geographical barriers and extending marketing reach. In response to this growing demand, Medical Asia 2026 offers a comprehensive suite of innovative digital exhibition solutions, including dedicated exhibitor pages, electronic catalogs, and virtual exhibition halls. These digital tools are seamlessly integrated with TradeAsia, enabling international buyers worldwide to effortlessly discover exhibitors and explore products in depth. Through the platform, buyers can visit individual manufacturer pages, review detailed product information, submit inquiries, and communicate with exhibitors via real-time messaging. This highly interactive and user-friendly experience facilitates smooth communication, enhances buyer engagement, and fosters meaningful business connections between exhibitors and global buyers, ultimately creating valuable commercial opportunities.

TradeAsia (www.e-tradeasia.com) has been providing comprehensive B2B international trade services for buyers and sellers worldwide since 1997. With nearly three decades of industry experience, TradeAsia is recognized as one of the most established and professional global trade platforms. Today, the platform serves millions of members worldwide, featuring more than 600,000 verified suppliers and millions of up-to-date product listings across diverse industries. Every day, thousands of professional buyers from around the world use TradeAsia to source products, connect with suppliers, and explore new business opportunities. As a leading trade promotion channel in Asia, TradeAsia continues to facilitate efficient cross border trade and foster long term partnerships between global buyers and suppliers.

TradeAsia also collaborates with hundreds of trading organizations around the world to exchange marketing and promotional opportunities. As a result, suppliers who showcase their products on TradeAsia gain the chance to be featured across the publicity channels of multiple trade platforms and exhibition organizers worldwide, greatly enhancing their international visibility and marketing reach. In addition, during the period of Medical Asia 2026, promotional messages will be broadcast globally, further amplifying exposure for participating suppliers and connecting them with a wider international audience.

Hashtag: #TradeAsia

The issuer is solely responsible for the content of this announcement.

Recharge Power Awarded Taiwan’s Largest Solar-Plus-Storage EPC Project from HEXA Renewables

By
Advertorial Desk
-

Project highlights Recharge Power’s utility-scale system integration and EPC delivery capabilities

TAIPEI, Feb. 3, 2026 /PRNewswire/ — Recharge Power Co., Ltd., the energy storage subsidiary of J&V Energy Technology Co., Ltd. (6869), has been selected to undertake the Engineering, Procurement, and Construction (EPC) works for a large-scale solar-plus-storage project. With a total capacity of 48MW/185.7MWh, this project, as part of HEXA Renewables’ solar-plus-storage integration initiative, demonstrates Recharge Power’s capabilities in hybrid system integration and utility-scale storage delivery.

HEXA Renewables, an international renewable energy platform, focuses on building a diversified portfolio of renewable generation and energy storage integration projects in Taiwan. This collaboration reflects Recharge Power’s track record in complex project execution and system integration.

This solar-plus-storage project, featuring 48MW/185.7MWh of battery storage, is scheduled to break ground in the first half of this year. The deployment of this large-scale energy storage system will provide peak shaving and load shifting services to mitigate the intermittency of renewable power, while improving grid dispatch flexibility, overall resilience, and solar penetration. The project is expected to generate significant EPC revenue during the construction phase and, upon completion, rank among one of Taiwan’s most significant utility-scale solar-plus-storage facilities.

“Recharge Power possesses strong system integration capabilities, supported by established project management, construction coordination, and quality control expertise,” said Spencer Feng, Chief Executive Officer of Recharge Power. “This expertise enabled us to complete Taiwan’s first grid-connected solar-storage project with our parent company, J&V Energy Technology, in December 2023. This project forms part of  HEXA Renewables’ solar-plus-storage integration efforts, standing as one of the largest solar-plus-storage facilities in Taiwan. It further validates our EPC and O&M capabilities in energy storage systems and builds on our accumulated experience in this field.”

Beyond Taiwan’s first solar-plus-storage project, Recharge Power has developed several pioneering and benchmark storage projects in the local market, including Taiwan’s first Automatic Frequency Control (AFC) project, Taipower’s first grid-connected substation energy storage project, and a 200MW/335MWh large-scale storage project. These projects illustrate Recharge Power’s end-to-end technical integration and execution capabilities across multiple grid and energy storage use cases.

“In line with our overall strategy, utility-scale energy storage has become foundational infrastructure supporting the energy transition and grid stability as renewable penetration increases,” said Kai Tan, Deputy General Manager of J&V Energy Technology. “Securing Taiwan’s largest solar-plus-storage EPC project not only solidifies the Group’s leadership position in the domestic storage market, but also creates a vital track record for its further global expansion.”

Mr. Tan added that the Group will draw on its experience from Taiwan’s large-scale solar-plus-storage and grid-level storage projects to strengthen technological integration and operational capabilities. “We plan to expand our storage business into overseas markets with high growth potential, establishing a replicable and scalable international business model. This will sustain long-term growth and deliver deployable, integrated solutions that enable the global energy transition.”

About Recharge Power Co., Ltd.

Recharge Power Co., Ltd., a Battery Energy Storage System Integrator (BESSI) under J&V Energy Technology Co., Ltd., is one of the few companies in Taiwan offering fully integrated, end-to-end services for grid-scale energy storage systems. Its comprehensive solutions and services cover system design review, industrial control and communication systems, site construction, installation, commissioning, as well as long-term operation and maintenance (O&M) and qualified trading services.

To date, its cumulative installed storage capacity exceeds 370MW/886MWh, encompassing multiple milestones in Taiwan’s storage development. These include Taiwan’s first AFC demonstration project, Taipower’s first grid-connected substation energy storage project, the first grid-connected solar-plus-storage project, and the largest privately-owned storage project in Taiwan, demonstrating mature system integration and disciplined engineering execution.

Beyond Taiwan, Recharge Power has continued to build its presence in the Japanese storage market, with several projects already grid-connected and a 24/7 O&M system established across Taiwan and Japan. This provides an operational foundation for the global growth of J&V Energy Technology’s storage business.

Recharge Power Co., Ltd., a subsidiary of J&V Energy Technology Co., Ltd., has been awarded the EPC contract for a large-scale solar-plus-storage project from HEXA Renewables, with a total capacity of 48MW/185.7MWh. Upon completion, it will become one of Taiwan's notable utility-scale integrated solar-plus-storage assets. (Image: Aerial photo of the solar farm for the project.)
Recharge Power Co., Ltd., a subsidiary of J&V Energy Technology Co., Ltd., has been awarded the EPC contract for a large-scale solar-plus-storage project from HEXA Renewables, with a total capacity of 48MW/185.7MWh. Upon completion, it will become one of Taiwan’s notable utility-scale integrated solar-plus-storage assets. (Image: Aerial photo of the solar farm for the project.)

 

Saddle Up for a Renewed Lunar New Year as iShopChangi Reimagines Festive Rituals for 2026

By
Advertorial Desk
-

Saddle up for the Year of the Horse with iShopChangi as it brings curated festive finds together to refresh your Lunar New Year rituals for 2026. From festive gifting and beauty glow-ups to home essentials, wines and spirits, and gourmet treats, skip the festive rush with carefully selected picks made for the season as you start the new year feeling renewed. Alongside these Lunar New Year favourites, take home the exclusive iShopChangi x Good Addition Prosperity Tile Set, a collaboration with Andrea Chong.

SINGAPORE, Feb. 3, 2026 /PRNewswire/ — From now to 28 February 2026, travellers and non-travellers can get into the Lunar New Year spirit and refresh festive rituals with iShopChangi, offering curated festive finds and first-to-launch exclusives across fashion, beauty, wine and spirits, and lifestyle essentials at tax- and GST-absorbed prices, flying or not. Also featured this season is the exclusive iShopChangi x Good Addition Prosperity Tile Collectible, created in collaboration with local style icon Andrea Chong. Alongside curated selections, breeze through festive prep with on-demand delivery and gift-wrapping services.


Curated Lunar New Year Finds with an Exclusive Festive Touch

From standout gifts to party-ready picks, iShopChangi’s Lunar New Year curation has every celebration covered. Shop by mood and mission with collections made for Thoughtful Gifters picking out luxury beauty deluxe sets, fashion finds, and the latest tech from names like SK-II, Goldheart, and Sony. Efficient Hosts can stock up on wines, spirits, candles, and gourmet snacks, including festive favourites like cognac from Hennessy. And for the Glam Squad, go all out with beauty sets, fashion accessories, and health picks from brands like Kinohimitsu.

In addition to festive finds, mark the season with the exclusive iShopChangi x Good Addition Prosperity Tile Set, created in collaboration with local style icon Andrea Chong and her fashion brand Good Addition. Designed with Good Addition’s brocade motifs, festive yet calm colours, iShopChangi’s travel-inspired details, and a playful Otter design, the set puts a modern spin on a timeless ritual. Available for purchase at S$228 with a minimum spend of S$120.

Ring in the New Year with Festive Perks

Get festive-ready with curated selections made for the moments that matter most during the New Year. Whether it’s choosing thoughtful gifts, setting the mood for hosting, or dialling up your festive glam, iShopChangi brings together handpicked finds across beauty, fashion, wine and spirits, and home essentials. Indulge in exclusive finds and savings of up to 60% across Lunar New Year favourites from brands like SK-II, Hennessy, Sony, Kinohimitsu, Goldheart, and more.

Secure these festive promo codes and enjoy Lunar New Year savings.*

Lunar New Year Sale (For Non-Travellers and Travellers)

From now to 28 February 2026

Code

Description

LNY12

12%* off with no min. spend, capped at S$50

LNY15

15%* off with min. spend S$500, capped at S$120

Exclusive Lunar New Year Beauty Sale (For Travellers – Beauty Only)

LNY25B

25%* off with min. spend S$700, capped at S$300

*T&Cs and product exclusions apply. Refer to https://www.ishopchangi.com/en/campaigns/rituals2026 for full terms and conditions.

To round things off, make festive prep even easier with premium gift-wrapping services* for just S$5, and take advantage of On-Demand Delivery when time is tight. Place your order by 5PM (Monday–Saturday) and receive it within 2 hours for S$10, or enjoy complimentary 2-Hour On-Demand Delivery with a minimum spend of S$200*.

*Visit iShopChangi’s website for more details.

Celebrate New Beginnings with Festive Rewards

This New Year, enjoy more than festive finds on iShopChangi as celebrations come with extra rewards. Explore curated seasonal collections to celebrate the new season in style.

And there’s more for newcomers! For new iShopChangi shoppers, the rewards start immediately. Use the promo code [ISCNEW20] at checkout with a minimum spend of S$79 to enjoy an extra S$20 off your first purchase. New to Changi Pay? Enjoy S$10 off your first purchase of S$50 or more when you use Changi Pay at checkout.

Worried about delivery? As a non-traveller, you can cart out at tax-absorbed prices on iShopChangi and have your items delivered to you for free when you spend at least S$59 and provide a Singapore residential address for delivery. Alternatively, pick up selected products from the T2 Arrival (Public Area) iShopChangi Counter.

Travelling around the world? Enjoy the ultimate convenience and flexibility by shopping for your favourite items up to 30 days in advance and as close as 12 hours before your flight. Collect your order at the various Departure and Arrival Collection Centres. Alternatively, have it conveniently delivered to a local residential address for free with a minimum spend of S$59; an S$8 delivery fee applies for orders below S$59.

About iShopChangi 

iShopChangi was launched in 2013 as an extension of Changi Airport’s promise to deliver greater comfort and convenience to travellers in its suite of airport retail offerings. Passengers can browse and purchase tax- and duty-free products across all terminals between 30 days to 12 hours pre-flight on the e-store – and choose to collect their items at Collection Centres within departure, upon arrival or have them delivered free in Singapore. Providing easy access to over 30,000 products across 900 brands and exclusives such as Changi First product launches, the site has since received global recognition with its award for Best Website – Retail Customer Facing at The Moodies: the Airport and Travel Retail Digital Media Awards 2018. In early 2020, the e-commerce store started to retail a selection tax- and duty-absorbed products to Singapore-based residents without the need to fly.

Facebook: https://www.facebook.com/iShopChangi
Instagram: https://www.instagram.com/ishopchangi
X: https://x.com/changiairport
YouTube: https://www.youtube.com/c/changiairport

Xinhua Silk Road: 2026 Global Youth Spring Festival Gala Vietnam sub-venue events held in Hanoi, Hai Phong to boost youth exchanges

By
Advertorial Desk
-

BEIJING, Feb. 3, 2026 /PRNewswire/ — The Vietnam sub-venue events of the 2026 Global Youth Spring Festival Gala co-organized by relevant authorities in Vietnam and south China’s Guangxi Zhuang Autonomous Region were held successively in Hanoi and Hai Phong from January 28 to 29.

The events vividly showcased the profound cultural integration between China and Vietnam through various forms such as cultural performances, intangible cultural heritage experiences, and street flash mobs, promoting emotional resonance between the youth of the two countries and injecting new vitality into the traditional friendship of the two sides in the new era.

The gala held in Hanoi on January 28 included 12 cultural and artistic programs that blend traditional and modern, Chinese and Vietnamese characteristics. Actors from both China and Vietnam performed on the same stage, weaving a cross-border youth symphony together.

An intangible cultural heritage fair was also set up at the gala site, and the audience could participate in interactive activities such as calligraphy writing and intangible cultural heritage painting, experiencing both Chinese and Vietnamese cultures.

Rich cultural interactive activities were held in the central park of Hai Phong City on January 29, with Chinese and Vietnamese young artists and volunteers extending the festive atmosphere to the streets of the city.

In the flash mob performance segment, Chinese and Vietnamese calligraphers wrote auspicious Chinese characters as well as Vietnamese blessings, conveying best wishes crossing languages. Young singers and dancers performed songs and dances that blended Chinese and Vietnamese characteristics, driving the audience to move with the music and attracting waves of applause.

Touhu, a traditional Chinese game also known as pitch-pot, and blessing wall check-in among other interactive activities held on the site lured many local residents and tourists to participate in, with many of them sharing the wonderful moments through social media, achieving offline and online resonance.

Original link: https://en.imsilkroad.com/p/349441.html 

Total Investment of Approx. USD 8.8 Million in Malaria, Tuberculosis, and NTD R&D Projects with Partners Including Mahidol University, Barcelona Institute for Global Health, and Eisai

By
Advertorial Desk
-

TOKYO, Feb. 3, 2026 /PRNewswire/ — The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.39 billion (USD 8.8 million1) in six R&D projects for the development of drugs, diagnostics and vaccines for malaria, tuberculosis (TB), and neglected tropical diseases (NTDs).2 

Investment of JPY 648 million (approx. USD 4.1 million1) for development of an mRNA vaccine to reduce infection and transmission of vivax malaria
Malaria caused by Plasmodium vivax remains a major challenge to malaria elimination efforts due to the parasite’s ability to form dormant liver-stage hypnozoites. These dormant parasites may reactivate months or even years after the initial infection, causing recurrent episodes of malaria. In addition to triggering repeated blood infections, reactivation enables transmission back to mosquitoes, allowing the disease to persist within communities. To address this problem, the GHIT Fund is investing JPY 648 million (USD 4.1 million1) in a global partnership aimed at developing an mRNA vaccine to reduce infection and transmission of vivax malaria. This project is being led by Mahidol University and Chulalongkorn University in Thailand, and Ehime University in Japan. The investment builds on a prior GHIT-supported project3 that received approximately JPY 70 million (USD 0.4 million1) between 2023 and 2025.

Investment of JPY 93 million (approx. USD 0.6 million1) in diagnostic registration and JPY 183 million (USD 1.1 million1) in drug development for Chagas disease
Chagas disease is a parasitic infection primarily transmitted through the bite of triatomine bugs. It is estimated that more than seven million people worldwide are infected, with the majority of cases occurring in Latin America.4 Mother-to-child transmission also poses a significant public health challenge, making early diagnosis and prompt treatment essential. For the control of congenital Chagas disease, the GHIT Fund is investing JPY 93 million (USD 0.6 million1) in the registration of a point-of-care diagnostic test in Argentina and Bolivia. This project is led by ISGlobal (the Barcelona Institute for Global Health), a research institute in Spain, and Eiken Chemical Co., Ltd. in Japan. The GHIT Fund is also investing approximately JPY 183 million (USD 1.1 million1) in lead identification, which represents an early-stage step in the development of new drugs for Chagas disease being led by Eisai Co., Ltd. and others.

In addition, the GHIT Fund will invest a total of approximately JPY 466 million (approx. USD 2.9 million1) in the following three R&D projects:

  1. Facilitating local universal TB testing with Lung Flute ECO (FLUTTE): Validation in children, health care workers, and people living with HIV(PLHIV) with robust comparators for TB testing by the Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Acoustic Innovations Co., Ltd., Institute of Tropical Medicine, the Aurum Institute, Stellenbosch University, Instituto Nacional de Saúde and World Alliance for Lung and Intensive Care Medicine in Uganda.
  2. Development of a novel P. falciparum multistage vaccine by Ehime University, Sumitomo Pharma Co., Ltd., PATH, Statens Serum Institut and University of Copenhagen.
  3. AI-guided approaches for schistosomiasis drug discovery by Aberystwyth University and University of Dundee in the UK and BrightCore, Inc. in Japan.

Please refer to Appendix 1 for detailed descriptions on these projects and their development stages.

The six projects funded in this round bring together partners from a total of 13 countries. Since its inception, the GHIT Fund has worked with more than 210 research and development partners, including more than 140 overseas institutions. The GHIT Fund serves as a bridge connecting pharmaceutical companies, universities, and research institutes in Japan with their counterparts around the world.

As of December 31, 2025, there are 43 ongoing projects, including 19 discovery projects, 12 preclinical projects, and 12 clinical trials5 in the GHIT Fund’s portfolio. The total amount of investments since 2013 is JPY 42.5 billion (USD 271 million1) (Appendix 2).

1 USD 1 = JPY 156.53, the approximate exchange rate on December 30, 2025.
2 These awarded projects were selected and approved as new investments from among proposals to RFP2024-002 and RFP2025-001 for the Product Development Platform, the Target Research Platform, and the Hit-to-Lead Platform, which were open for applications from June 2024 to July 2025.
3 Project details: https://www.ghitfund.org/investment/portfoliodetail/detail/207/en
4 WHO: https://www.who.int/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis)
5 This number includes projects in the registration phase.

The GHIT Fund is a Japan-based international public-private partnership (PPP) fund that was formed between the Government of Japan, multiple pharmaceutical companies, the Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests in and manages an R&D portfolio of development partnerships aimed at addressing neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases, which afflict the world’s vulnerable and underserved populations. In collaboration with global partners, the GHIT Fund mobilizes Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases.
https://www.ghitfund.org/

Appendix 1. Project Details  

ID: G2025-112

Project Title

Development of a highly efficacious multistage mRNA vaccine formulation to prevent P. vivax infection and transmission

Collaboration

Partners

1. Mahidol University (Thailand)

2. Ehime University (Japan)

3. Chulalongkorn University (Thailand)

Disease

Malaria

Intervention

Vaccines

Stage

Lead Optimization

Awarded Amount

JPY 648,081,450 (USD 4.1 million)

Status

Continued project

Summary

[Project objective]

This project aims to develop a multistage mRNA vaccine capable of reducing both infection and transmission of P. vivax

 

[Project design]

Researchers from Mahidol, Chulalongkorn, and Ehime Universities are teaming up to develop a new mRNA vaccine that can both prevent infection and stop the spread of P. vivax. The vaccine will target two key proteins: PvCSP, which is involved in the early stages of infection, and Pvs230, which helps the parasite spread from humans to mosquitoes. The team will first test different versions of the PvCSP mRNA to find the most promising one, then fine-tune the best combination of PvCSP and Pvs230. Promising vaccine formulas will be tested in non-human primates to identify the most effective option. Once a lead candidate is selected, they will produce a high-quality vaccine suitable for human trials. All vaccine versions will use a clinically proven lipid nanoparticle (LNP) system to deliver the mRNA. Success will be evaluated by the vaccine’s ability to generate antibodies that block the parasite from infecting liver cells and prevent its transmission to mosquitoes.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/251/en

ID: G2025-121

Project Title

Trypanosoma cruzi-LAMP: A molecular point-of-care test for the control of congenital Chagas disease – from prototype to product

Collaboration

Partners

1. Barcelona Institute for Global Health (ISGlobal/Spain)

2. Eiken Chemical Co., Ltd. (EIKEN/Japan)

3. Consejo Nacional de Investigaciones Científicas y Técnicas- Instituto de Investigaciones en Ingeniería Genética y Biología Molecular “Dr. Héctor N. Torres” (CONICET-INGEBI/Argentina)

4. Fundación Salud Naturaleza Integral (SANIT/Bolivia)

5. Wiener lab (WIENER/Argentina)

Disease

Chagas disease

Intervention

Diagnostic

Stage

Registration

Awarded Amount

JPY 93,142,925 (USD 0.6 million)

Status

Continued project

Summary

[Project objective]

To license the T. cruzi-LAMP in Argentina and Bolivia, respectively in front of ANMAT and AGEMED regulatory agencies. Additionally, both industrial partners involved (EIKEN and WIENER) will reach a Memorandum of Understanding (MOU) that provides the context for the subsequent commercialization of the technology. At the same time, we will promote the use of the LAMP for improved diagnosis of congenital Chagas disease. Enabling the adoption of this tool will increase access, aligning to the WHO 2030 roadmap for Neglected Tropical Diseases, and contributing to the PAHO Elimination of Mother-To-Child Transmission (EMTCT) of infections initiative.

 

[Project design]In G2025-121, coordinated again by ISGlobal, we will extend the data of former project G2020-203 on the use of heparinized and dried blood spots (DBS) newborns samples in the study site of Yacuiba (Gran Chaco province, department of Tarija, Bolivia) operated by SANIT. These new data will complement the existing body of evidence, including prior analytical performance results generated by Eiken and CONICET-INGEBI, as well as the G2020–2023 clinical validation studies. In addition, performance data produced by Wiener using the T. cruzi-LAMP kits assembled at its manufacturing facility in Argentina will be incorporated. Together, this comprehensive dataset will underpin the preparation of the regulatory dossier and facilitate formal interactions with ANMAT and AGEMED, advancing the licensing and market authorization of the T. cruzi-LAMP diagnostic prototype in Argentina and Bolivia. The newly generated results will play a key role to respond the regulatory agencies requests, which include the analytical validation work conducted within the T. cruzi-LAMP verification studies led by Wiener.

Moreover, with the goal of recommending a change in the diagnosis policy to generalize a timely access to diagnosis (and treatment), we will advocate towards the adoptability of the technology through regular meetings with the competent health care authorities at both regional and national levels, as well as internationally to the PAHO and WHO.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/256/en  

ID: H2025-101

Project Title

Hit-to-Lead Optimization of Phosphodiesterase Inhibitors for the Treatment of Chagas Disease

Collaboration

Partners

1. Eisai Co., Ltd. (Japan)

2. Drugs for Neglected Diseases initiatives (DNDi/Switzerland)

3. Universidad Nacional de La Plata (UNLP/Argentina)

4. Fundación Instituto de Investigaciones en Ingeniería Genética y Biología Molecular (Fundación INGEBI/Argentina)

5. Instituto de Investigaciones en Microbiología y Parasitología Médica (IMPaM/Argentina)

Disease

Chagas disease

Intervention

Drug

Stage

Lead Identification

Awarded Amount

JPY 183,021,439 (USD 1.1 million)

Status

Continued project

Summary

[Project objective]

We propose to conduct a hit-to-lead campaign of phosphodiesterase (PDE) inhibitors for Chagas disease. We will leverage findings from a previous GHIT-funded project for the generation of structure-activity relationship (SAR) data to advance a medicinal chemistry campaign. We aim to identify compounds with favorable profiles and in vivo efficacy using an acute model of Chagas disease. This work represents a crucial contribution to the drug discovery pipeline as the endpoint for this proposal is the identification of leads that are primed for further optimization, bringing us closer to delivering an urgently needed, novel mechanism-of-action drug candidate for Chagas disease.

 

[Project design]New compounds will be subjected to iterative cycles of design, synthesis, and profiling in in vitro potency, selectivity, and DMPK assays, followed by in vivo PK studies. Structure-activity and structure-property relationships gleaned from these activities will be used to continually refine our analog design hypotheses. Potent analogs with acceptable in vitro and in vivo profiles will be progressed for in vivo efficacy testing using the Chagas acute model.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/252/en  

ID: G2024-105

Project Title

Facilitating Local Universal TB Testing with Lung Flute ECO (FLUTTE):
Validation in Children, Health Care Workers, and People Living with HIV(PLHIV) with Robust Comparators

Collaboration

Partners

1. The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association
(RIT-JATA/Japan)

2. Acoustic Innovations Co., Ltd (Japan)

3. Institute of Tropical Medicine (ITM/Belgium)

4. The Aurum Institute (Republic of South Africa and Republic of Mozambique)

5. Stellenbosch University (Republic of South Africa)

6. Instituto Nacional de Saúde (INS/Republic of Mozambique)

7. World Alliance for Lung and Intensive Care Medicine in Uganda
(WALIMU/Republic of Uganda)

Disease

Tuberculosis

Intervention

Diagnostics

Stage

Product Validation

Awarded Amount

JPY 281,985,836 (USD 1.8 million)

Status

Continued project

Summary

[Project objective]

The goal is to generate robust scientific evidence for WHO endorsement of the Lung Flute ECO by 2027. The project will assess LFE performance in:

  1. Targeted Universal TB Testing (TUTT) among health-care workers and PLHIV unable to expectorate.
  2. Paediatric TB diagnosis comparing LFE with saline induction, nasopharyngeal aspirates, and tongue swabs; and
  3. Community screening combined with digital chest X-ray and computer-aided detection (CAD).
    The project also aims to establish sustainable local manufacturing in Africa and Asia.

 

[Project design]

A network of clinical trials in South Africa, Mozambique, and Uganda will enroll over 8,000 participants using randomized or crossover designs with molecular and culture-based TB diagnostics as references. Data on diagnostic yield, safety, acceptability, and cost-effectiveness will be harmonized for pooled analysis to meet WHO guideline review criteria. Parallel activities include technology transfer, manufacturer training, and market-entry preparation for LMICs.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/253/en

ID: T2025-157

Project Title

Development of a novel P. falciparum multistage vaccine candidate based on PfCSP and PfRipr5

Collaboration

Partners

1.PATH (USA)

2. Ehime University (Japan)

3. Sumitomo Pharma Co., Ltd. (Japan)

4. Statens Serum Institut (SSI/Denmark)

5. University of Copenhagen (UCPH/Denmark)

 

Disease

Malaria

Intervention

Vaccine

Stage

Antigen Identification

Awarded Amount

JPY 99,989,845 (USD 0.6 million)

Status

New project

Summary

[Project objective]

The objective of this project is to generate robust preclinical data to support the advancement of a multistage (CS + BS) particle-based malaria vaccine candidate formulated with a potent adjuvant. Under our central hypothesis, a vaccine targeting both pre-erythrocytic (CS) and erythrocytic (BS) stages will provide additive and/or synergistic protection against P. falciparum by interrupting two sequential lifecycle stages. This dual-targeting strategy is designed to reduce progression to clinical disease in individuals not achieving full protection with current CS-based vaccines (RTS,S/AS01, R21/Matrix-M). Milestones for this project include:

  1. Generation and testing of potent CS and BS immunogens on a proven particle delivery platform in in vivo efficacy models.
  2. Testing admixed combinations of CS and BS particle-based immunogens in in vivo efficacy models.
  3. Generation of a single particle displaying both CS and BS immunogens.

 

[Project design]This project is built on the successful completion of the following activities: 

  1. A reliable system for preclinical efficacy testing of CS vaccine candidates; 
  2. Evidence that particle delivery is preferred for efficacy of CS immunogens; 
  3. Access to a robust, Phase 3 clinically validated particle delivery platform for preclinical and clinical testing; 
  4. Identification of a potent BS immunogen; 
  5. Down-selection of the most potent region of PfRipr; and 
  6. Access to potent TLR-7 agonist adjuvants. 

The project will be initiated by generating and evaluating potent CS and BS immunogens displayed on the clinically validated AP205 particle platform and assessing their functional efficacy in vivo. After completing the individual antigen testing, we will proceed to evaluate the admixed combination of CS and BS immunogens presented on AP205 particles in vivo. This phase will determine whether co-administration preserves—or even enhances—the immunogenicity of each antigen, will identify potential immune interference or synergistic effects, and will define the optimal CS to BS ratio to be administered.

Once the admixed administration has been evaluated and ratios of CS to BS have been defined, a single, co-displayed particle that presents both CS and BS antigens on the AP205 platform will be constructed and characterized. This co-display approach on a single, easy-to-manufacture nanoparticle aligns with the project goal of simplified, cost-effective, multistage vaccine delivery.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/254/en  

ID: T2025-151

Project Title

AIH2L: Artificial Intelligence Guided Strategies to Identify New Anti-Schistosomal Hit to Lead Candidates.

Collaboration

Partners

1. Aberystwyth University (UK)

2. BrightCore, Inc. (Japan)

3. University of Dundee (UK)

Disease

Schistosomiasis

Intervention

Drug

Stage

Target Identification

Awarded Amount

JPY 84,482,057 (USD 0.5 million)

Status

New project

Summary

[Project objective]

The primary goal of this project is to deliver a small number of multi-lifecycle stage (schistosomula, juveniles and adults) active chemical series ready to enter the hit-to-lead phase of anti-schistosomal drug discovery. To achieve this goal, we will combine AI-guided approaches for drug discovery with high-throughput, whole-organism imaging platforms to phenotype schistosomes and expertise in early-stage drug discovery for schistosomiasis including medicinal chemistry and DMPK. The compounds developed here will be carried forward in subsequent projects as putative replacement drugs for praziquantel.

 

[Project design]Using existing phenotypic datasets, AI models will first be built to identify chemical features associated with anti-schistosomal activity and run these trained models on large chemical libraries to identify new compounds predicted to display potential anti-schistosomal activity.

 

Using high-throughput phenotyping platforms, approximately 100 of the prioritized compounds will first be co-cultured with S. mansoni schistosomula (10 µM final concentration) for 72 h. Active molecules will be subjected to dose response titrations and those displaying EC50s less than 10 µM will subsequently be tested against 7-week adult male and female worms (20 µM final concentration) for 72 h. Actives will subsequently be tested in dose response titrations for EC50 determinations. Compounds with adult worm EC50s less than 20 µM will subsequently be tested against 3-week juvenile worms in dose response assays. Compounds demonstrating EC50s less than 10 µM in schistosomula, 20 µM in adult worms and 20 µM juvenile worms will be progressed as hits.  

 

Confirmed hits will be tested for cytotoxicity, metabolic stability, aqueous solubility and lipophilicity. Focused hit expansion plans for the most promising actives will aim to assess the potential to improve potency and DMPK profile, explore synthetic tractability and identify key areas for further optimization. Commercial analogs or, if available, analogs in our existing compound collection will also be tested. Series that meet Compound Progression Criteria for a Validated Hit Series will be screened against S. mansoni parasites during ex vivo co-culture. Compounds demonstrating EC50s less than 3 µM in schistosomula, 3 µM in adult worms and 3 µM juvenile worms will be identified as H2L candidates.

Project Detail

https://www.ghitfund.org/investment/portfoliodetail/detail/255/en  

*All amounts are listed at an exchange rate of USD 1 = JPY 156.53, the approximate exchange rate on December 30, 2025.

Appendix 2. Investment Overview (as of December 31, 2025)

Investments to date
Total investments: JPY 42.5 billion (USD 271 million1)
Total invested projects: 144 (43 active projects and 101 completed projects)

To learn more about the GHIT Fund’s investments, please visit
Investment Overview: https://www.ghitfund.org/investment/overview/en
Portfolio: https://www.ghitfund.org/investment/portfolio/en
Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en

For more information, contact:
Nancy Moss at +1-908-606-8940 or nmoss@burness.com
Eriko Mugitani at +81-36441-2032 or eriko.mugitani@ghitfund.org

Qualcomm AI Program for Innovators 2026 – APAC Officially Kicks Off – empowering startups across Japan, Singapore, and South Korea to lead the AI innovation

By
Advertorial Desk
-

Highlights

  • Qualcomm launches Qualcomm AI Program for Innovators (QAIPI) 2026 – APAC, supporting startups in Japan, Singapore, and South Korea to develop innovative edge AI solutions across industries
  • Startups gain comprehensive support and resources, including access to Qualcomm Dragonwing™ and Snapdragon® platforms, the Arduino® UNO Q development board, technical guidance and mentorship, a grant of up to US$10,000, and eligibility for up to US$5,000 in patent filing incentives, accelerating AI product development and deployment.
  • Applications are open now through April 30, 2026.

SAN DIEGO, Feb. 3, 2026 /PRNewswire/ — Qualcomm Technologies, Inc. today announced the official launch of the Qualcomm AI Program for Innovators (QAIPI) 2026 – APAC, a regional startup incubation initiative that supports startups across Japan, Singapore, and South Korea in advancing the development and commercialization of innovative edge AI solutions.

Qualcomm AI Program for Innovators 2026 – APAC Officially Kicks Off
Qualcomm AI Program for Innovators 2026 – APAC Officially Kicks Off

Building on Qualcomm’s commitment to edge AI innovation, the second edition of QAIPI-APAC invites startups to develop intelligent solutions across a broad range of edge-AI applications using Qualcomm Dragonwing™ and Snapdragon® platforms, together with the new Arduino® UNO Q development board, strengthening their pathway toward global commercialization. The program supports startups building end-to-end AI use cases in sectors including consumer devices, healthcare, smart industry, smart cities, education, and industrial IoT, with a strong focus on scalability, deployment, and commercial readiness. Participating startups will also benefit from Qualcomm’s extensive global ecosystem, accessing technologies, technical guidance, and mentorship to move efficiently from concept to deployable products.

The Qualcomm AI Program for Innovators (QAIPI) empowers startups to develop and deploy scalable edge AI solutions, bringing intelligence closer to the edge across diverse real-world applications.
The Qualcomm AI Program for Innovators (QAIPI) empowers startups to develop and deploy scalable edge AI solutions, bringing intelligence closer to the edge across diverse real-world applications.

Applications for QAIPI 2026 – APAC are open until April 30, 2026 (11:59 p.m. PST) and will be evaluated based on innovation, technical feasibility, potential societal impact, and commercial relevance. The program will be implemented in two phases. The application phase is open to eligible startups incorporated and registered in Japan, Singapore, or South Korea. Shortlisted startups will enter the mentorship phase, receiving one-on-one guidance, online training, technical support, and access to Qualcomm-powered hardware platforms and development kits for product development. They will also receive a shortlist grant of up to US$10,000 and may be eligible for a patent filing incentive of up to US$5,000. At the conclusion of the program, shortlisted startups may be invited to showcase their innovations at a signature Demo Day in late 2026, engaging with industry leaders, investors, and potential collaborators across the APAC innovation ecosystem.

QAIPI-APAC shortlisted startups showcase their edge AI innovations at the 2025 Demo Day, engaging with industry leaders, investors, and ecosystem partners.
QAIPI-APAC shortlisted startups showcase their edge AI innovations at the 2025 Demo Day, engaging with industry leaders, investors, and ecosystem partners.

In addition to technical and product development support, Qualcomm continues to help QAIPI-APAC startups connect with global markets and international innovation ecosystems. In 2025, Qualcomm has supported QAIPI-APAC shortlisted startups through participation in major industry events, including the Singapore Week of Innovation and Technology (SWITCH) 2025 and a signature Demo Day in Seoul, enabling them to engage with global customers, partners, and investors. Building on this momentum, shortlisted startups are also invited to participate in the 2026 Smart City Summit & Expo (SCSE) this March in Taiwan, further accelerating real-world validation, cross-market collaboration, and pathways toward global commercialization.

Qualcomm leads QAIPI-APAC startups in connecting with global innovation ecosystems, including participation in the SWITCH 2025 event in Singapore, to expand cross-border collaboration and market opportunities.
Qualcomm leads QAIPI-APAC startups in connecting with global innovation ecosystems, including participation in the SWITCH 2025 event in Singapore, to expand cross-border collaboration and market opportunities.

Following its acquisition of Arduino, a leading open-source hardware and software provider, Qualcomm has expanded the tools and developer ecosystem available to innovators. The new Arduino UNO Q open-source development board, powered by Qualcomm Dragonwing, supports Linux applications, real-time control, and lightweight AI inferencing, enabling startups to accelerate edge-intelligent applications. To speed up the development of edge AI solutions across diverse use cases, startup teams can leverage the Qualcomm® AI Hub, a developer-focused platform offering a growing catalog of pre-optimized AI models, alongside Edge Impulse, a leading platform for building and deploying tinyML and edge-AI models from real-world sensor data, the Arduino Project Hub, and curated GitHub® repositories with optimized models and end to end demos.  These resources help reduce time and effort, enabling faster development, deployment, and iteration cycles.

The Arduino® UNO Q development board, powered by Qualcomm Dragonwing™, provides startups with a scalable platform for developing and deploying edge AI solutions.
The Arduino® UNO Q development board, powered by Qualcomm Dragonwing™, provides startups with a scalable platform for developing and deploying edge AI solutions.

“The rapid shift toward edge AI is unlocking new opportunities for innovation, productivity, and economic growth across the Asia-Pacific region,” said O.H. Kwon, Senior Vice President and President, Qualcomm APAC. “Through the Qualcomm AI Program for Innovators, we are helping startups transform ideas into scalable solutions and supporting innovators in leveraging hybrid and edge AI to create intelligent products with lower power consumption, higher efficiency, and enhanced privacy. By fostering a strong edge-AI ecosystem, we aim to empower the next generation of technology leaders and accelerate meaningful impact across industries and communities.”

“The first year of QAIPI in Japan, Singapore, and South Korea showcased AI’s leap from novel optics and healthcare to retail and humanoid robotics,” said Sudeepto Roy, Vice President of Engineering, Qualcomm Incorporated, and Lead of Qualcomm’s Global Ecosystem Development Program. “We are empowering startups with advanced platforms and vital IP protection to transform these breakthrough ideas into secure, patented, and deployable products. As we enter this new phase of edge AI, I am eager to see this year’s cohort accelerate real-world adoption and fortify the global innovation ecosystem.”

Applications for the Qualcomm AI Program for Innovators 2026 – APAC are open through April 30, 2026 (11:59 p.m. PST) and will be evaluated based on innovation, technical feasibility, potential societal impact and commercial relevance. Additional information, including eligibility requirements and official rules, is available on the program website: www.qualcomm.com/ai-program-for-innovators/apac.

About Qualcomm

Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Our proven solutions drive transformation across major industries, and our Snapdragon® branded platforms power extraordinary consumer experiences. Building on our nearly 40-year leadership in setting industry standards and creating era-defining technology breakthroughs, we deliver leading edge AI, high-performance, low-power computing, and unrivaled connectivity. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress.

Qualcomm Incorporated includes our licensing business, QTL, and the vast majority of our patent portfolio. Qualcomm Technologies, Inc., a subsidiary of Qualcomm Incorporated, operates, along with its subsidiaries, substantially all of our engineering and research and development functions and substantially all of our products and services businesses, including our QCT semiconductor business. Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patents are licensed by Qualcomm Incorporated.

Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries.

Snapdragon, Qualcomm and Qualcomm Dragonwing are trademarks or registered trademarks of Qualcomm Incorprated.

Arduino and other Arduino marks and logos are trademarks of Arduino S.r.L.

Media Contact: qaipi_apac@qualcomm.com

1...1,2421,2431,244...6,587Page 1,243 of 6,587